Review

age (Merck & Co)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Merck & Co age
Age, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/age/age/pm41337697-35-52-57
Average 86 stars, based on 1 article reviews

age - by Bioz Stars, 2026-10

86/100 stars

Images

Vaccines:

Article Title: A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico
Article Snippet: .. Routine pediatric vaccines administered concomitantly with study vaccines, consistent with the ACIP recommendations, were: diphtheria, tetanus, acellular pertussis, inactivated polio, Haemophilus influenzae type b vaccine (DTaP5-IPV/Hib; Pentacel®, Sanofi) at 2, 4, 6, and 15–18 months of age, pneumococcal 13-valent conjugate vaccine (PCV13; Prevnar®13, Pfizer) at 2, 4, 6, and 12–15 months of age, pentavalent rotavirus vaccine (RotaTeq®, Merck & Co) at 2, 4, and 6 months of age, hepatitis B vaccine (ENGERIX-B®, GlaxoSmithKline) at 2 and 6 months of age, and measles-mumps-rubella vaccine (MMR; M-M-R® II, Merck & Co) and varicella vaccine (VARIVAX®, Merck & Co) at 12–15 months of age. .. Participants in Group 1b and in Group 2 also received hepatitis A vaccine (HAVRIX®, GlaxoSmithKline) at 15–18 months of age as part of the study; those in Group 1a did not receive hepatitis A vaccination during the study but were expected to be vaccinated, as per standard practice, after completion of the final study visit.

Article Title: A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.
Article Snippet: .. Routine pediatric vaccines administered concomitantly with study vaccines, consistent with the ACIP recommendations,18 were: diphtheria, tetanus, acellular pertussis, inactivated polio, Haemophilus influenzae type b vaccine (DTaP5-IPV/Hib; Pentacel®, Sanofi) at 2, 4, 6, and 15–18 months of age, pneumococcal 13-valent conjugate vaccine (PCV13; Prevnar®13, Pfizer) at 2, 4, 6, and 12–15 months of age, pentavalent rotavirus vaccine (RotaTeq®, Merck & Co) at 2, 4, and 6 months of age, hepatitis B vaccine (ENGERIX-B®, GlaxoSmithKline) at 2 and 6 months of age, and measles-mumps-rubella vaccine (MMR; M-M-R® II, Merck & Co) and varicella vaccine (VARIVAX®, Merck & Co) at 12–15 months of age. .. Participants in Group 1b and in Group 2 also received hepatitis A vaccine (HAVRIX®, GlaxoSmithKline) at 15–18 months of age as part of the study; those in Group 1a did not receive hepatitis A vaccination during the study but were expected to be vaccinated, as per standard practice, after completion of the final study visit.

Review

age (Merck & Co)

Structured Review

Images

Related Articles

Vaccines:

Similar Products

Image Search Results